Tags

Type your tag names separated by a space and hit enter

Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.
Obstet Gynecol. 1989 Mar; 73(3 Pt 2):517-20.OG

Abstract

A 37-year-old woman with a symptomatic 18-mm prolactin-secreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Maryland, Baltimore.No affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

2915884

Citation

Katz, E, et al. "Successful Treatment of a Prolactin-producing Pituitary Macroadenoma With Intravaginal Bromocriptine Mesylate: a Novel Approach to Intolerance of Oral Therapy." Obstetrics and Gynecology, vol. 73, no. 3 Pt 2, 1989, pp. 517-20.
Katz E, Schran HF, Adashi EY. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstet Gynecol. 1989;73(3 Pt 2):517-20.
Katz, E., Schran, H. F., & Adashi, E. Y. (1989). Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstetrics and Gynecology, 73(3 Pt 2), 517-20.
Katz E, Schran HF, Adashi EY. Successful Treatment of a Prolactin-producing Pituitary Macroadenoma With Intravaginal Bromocriptine Mesylate: a Novel Approach to Intolerance of Oral Therapy. Obstet Gynecol. 1989;73(3 Pt 2):517-20. PubMed PMID: 2915884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. AU - Katz,E, AU - Schran,H F, AU - Adashi,E Y, PY - 1989/3/1/pubmed PY - 1989/3/1/medline PY - 1989/3/1/entrez SP - 517 EP - 20 JF - Obstetrics and gynecology JO - Obstet Gynecol VL - 73 IS - 3 Pt 2 N2 - A 37-year-old woman with a symptomatic 18-mm prolactin-secreting pituitary adenoma could not be managed with oral bromocriptine mesylate because of unacceptable gastrointestinal side effects. However, when given the medication intravaginally, the patient was successfully treated as assessed by evident tumor shrinkage and diminished secretory activity. Serum bromocriptine levels were approximately six to eight times higher than those reported after oral administration. The vaginal route may help reduce some of the adverse effects of bromocriptine mesylate experienced during oral administration and may possibly allow lowering of the overall effective dose by avoiding first liver passage. SN - 0029-7844 UR - https://www.unboundmedicine.com/medline/citation/2915884/Successful_treatment_of_a_prolactin_producing_pituitary_macroadenoma_with_intravaginal_bromocriptine_mesylate:_a_novel_approach_to_intolerance_of_oral_therapy_ DB - PRIME DP - Unbound Medicine ER -